Elevation Oncology Inc (ELEV) — Cash Flow-to-Debt Ratio
Elevation Oncology Inc (ELEV) has a Cash Flow-to-Debt Ratio of -0.36x as of March 2025, meaning its operating cash flow of $-12.71 Million could theoretically repay 0% of its total liabilities ($35.49 Million) in one year. Explore ELEV cash flow metrics to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Elevation Oncology Inc Cash Flow-to-Debt Ratio (2019–2024)
Historical debt coverage capacity for Elevation Oncology Inc across 6 annual periods. Also explore Elevation Oncology Inc total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Elevation Oncology Inc (2019–2024)
Year-by-year debt coverage analysis for Elevation Oncology Inc. For market capitalisation and broader financial context, see ELEV stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.02x | $-36.36 Million | $35.60 Million | ▲ +37.7% |
| 2023 | -1.64x | $-56.18 Million | $34.28 Million | ▲ +13.5% |
| 2022 | -1.89x | $-85.48 Million | $45.13 Million | ▲ +44.8% |
| 2021 | -3.43x | $-30.17 Million | $8.80 Million | ▼ -2799.7% |
| 2020 | -0.12x | $-12.30 Million | $103.99 Million | ▲ +83.1% |
| 2019 | -0.70x | $-5.45 Million | $7.79 Million | — |